A laminin 511 matrix is regulated by Taz and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells

Genes and Development

Volumn 29, Issue 1, 2015, Pages 1-6

  Chang, Cheng ^a   Goel, Hira Lal ^a   Gao, Huijie ^a,g   Pursell, Bryan ^a   Shultz, Leonard D ^b   Greiner, Dale L ^a   Ingerpuu, Sulev ^c   Patarroyo, Manuel ^d   Cao, Shiliang ^e   Lim, Elgene ^e   Mao, Junhao ^a   Kulju McKee, Karen ^f   Yurchenco, Peter D ^f   Mercurio, Arthur M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

^c UNIVERSITY OF TARTU   (Estonia)

^d KAROLINSKA INSTITUTE   (Sweden)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g SHANDONG UNIVERSITY   (China)

Author keywords

Cancer stem cell; Extracellular matrix; Integrin; Laminin; TAZ

Indexed keywords

HIPPO TRANSDUCER PROTEIN; LAMININ 10; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 6; LAMININ; LIGAND; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; BREAST CANCER; CANCER STEM CELL; CELL RENEWAL; CONTROLLED STUDY; POSITIVE FEEDBACK; PROTEIN EXPRESSION; BREAST TUMOR; EXTRACELLULAR MATRIX; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

BREAST NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; INTEGRIN ALPHA6BETA1; LAMININ; LIGANDS; NEOPLASTIC STEM CELLS; TRANSCRIPTION FACTORS;

EID: 84920450458     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.253682.114     Document Type: Article

References (32)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF.2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 100: 3983–3988.
2. Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E, Jones JC, et al. 2005. A simplified laminin nomenclature. Matrix Biol 24: 326–332.
3. Baccelli I, Trumpp A. 2012. The evolving concept of cancer and metastasis stem cells. J Cell Biol 198: 281–293.
4. Beck B, Blanpain C. 2013. Unravelling cancer stem cell potential. Nat Rev Cancer 13: 727–738.
5. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV. 2010. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 102: 1637–1652.
6. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al. 2011. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147: 759–772.
7. Dean M, Fojo T, Bates S. 2005. Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275–284.
8. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al. 2011. Role of YAP/TAZ in mechanotransduction. Nature 474: 179–183.
9. Goel HL, Mercurio AM. 2013. VEGF targets the tumour cell. Nat Rev Cancer 13: 871–882.
10. Goel HL, Pursell B, Chang C, Shaw LM, Mao J, Simin K, Kumar P, Vander Kooi CW, Shultz LD, Greiner DL, et al. 2013. GLI1 regulates a novel neuropilin-2/a6b1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med 5: 488–508.
11. Goel HL, Gritsko T, Pursell B, Chang C, Shultz LD, Greiner DL, Norum JH, Toftgard R, Shaw LM, Mercurio AM. 2014. Regulated splicing of the a6 integrin cytoplasmic domain determines the fate of breast cancer stem cells. Cell Reports 7: 1–15.
12. Iliopoulos D, Hirsch HA, Wang G, Struhl K. 2011. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci 108: 1397–1402.
13. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, et al. 2000. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 19: 6778–6791.
14. Kreso A, Dick JE. 2014. Evolution of the cancer stem cell model. Cell Stem Cell 14: 275–291.
15. Kumar P, Mukherjee M, Johnson JP, Patel M, Huey B, Albertson DG, Simin K. 2012. Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution. PLoS Genet 8: e1003027.
16. Lane SW, Williams DA, Watt FM. 2014. Modulating the stem cell niche for tissue regeneration. Nat Biotechnol 32: 795–803.
17. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, et al. 2010. Integrin a6 regulates glioblastoma stem cells. Cell Stem Cell 6: 421–432.
18. Mercurio AM. 1990. Laminin: multiple forms, multiple receptors. Curr Opin Cell Biol 2: 845–849.
19. Miner JH. 2008. Laminins and their roles in mammals. Microsc Res Tech 71: 349–356.
20. Piccolo S, Cordenonsi M, Dupont S. 2013. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res 19: 4925–4930.
21. Pinto CA, Widodo E, Waltham M, Thompson EW. 2013. Breast cancer stem cells and epithelial mesenchymal plasticity—implications for chemoresistance. Cancer Lett 341: 56–62.
22. Pouliot N, Kusuma N. 2013. Laminin-511: a multi-functional adhesion protein regulating cell migration, tumor invasion and metastasis. Cell Adhes Migr 7: 142–149.
23. Scheel C, Weinberg RA. 2012. Cancer stem cells and epithelial–mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22: 396–403.
24. Seguin L, Weis SM, Cheresh DA. 2014. Variety in the tumor microenvironment: integrin splicing regulates stemness. Cell Stem Cell 14:557–558.
25. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. 2006. Generation of a functional mammary gland from a single stem cell. Nature 439: 84–88.
26. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. 2006. Purification and unique properties of mammary epithelial stem cells. Nature 439: 993–997.
27. Streuli CH, Schmidhauser C, Bailey N, Yurchenco P, Skubitz AP, Roskelley C, Bissell MJ. 1995. Laminin mediates tissue-specific gene expression in mammary epithelia. J Cell Biol 129: 591–603.
28. Tang Y, Rowe RG, Botvinick EL, Kurup A, Putnam AJ, Seiki M, Weaver VM, Keller ET, Goldstein S, Dai J, et al. 2013. MT1–MMP-dependent control of skeletal stem cell commitment via a b1-integrin/YAP/TAZ signaling axis. Dev Cell 25: 402–416.
29. Varelas X. 2014. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 141: 1614–1626.
30. Visvader JE, Lindeman GJ. 2012. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10: 717–728.
31. Wong SY, Kumar S. 2014. Matrix regulation of tumor-initiating cells. Prog Mol Biol Transl Sci 126: 243–256.
32. Yu FX, Guan KL. 2013. The Hippo pathway: regulators and regulations. Genes Dev 27: 355–371.